Study Title

radiopharmtheranostics

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients with Advanced Solid Tumours

Study Details

Description:

This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Sponsor:

Radiopharm Theranostics

Contacts:

Aviral Singh, MD

aviral.singh@genesiscare.com

+61 08 93661542

Dimitris Voliotis, MD

dv@radiopharmtheranostics.com

+1 646 535 5017

Government Study Link:

NCT06824155 - Click here to see study on

ClinicalTrials.gov

Drug Details

177Lu-RAD202
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • HER2

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Australia

GenesisCare Murdoch

Perth, Western Australia, Australia

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468